A compound having the general formula, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, wherein X 51 is CH or N; X 52 -R 54 is N or C-R 57; X 53 is NR 55, N(R 55)C, C NR 55, O, C, C O, OC; N(R 55)SO 2, SO 2 N(R 55), S, SO, or SO 2; R 50 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 51 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; R 52 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; or wherein R 51 and R 52 can be joined together to form a 3- to 7-membered carbo- or heterocyclic ring; R 53 is -R 56, or -X 53 -R 56; R 55 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 66 is -(optionally substituted hydrocarbon group which contains from 5 to 20 carbon atoms and optionally 1 to 4 heteroatoms selected from O, N and S and which contains at least one ring); R 67 is -H, -Hal or -C 1-6 alkyl; R 58 is -H, -C 1-6 alkyl, or -(CH 2 CH 2 O) r H; R 59 is -H, or -C 1-6 alkyl; R is independently selected from -C 1-6 alkyl, -C -C 1-6 alkyl, -Hal, -CF 3, -CN, -COOR 58, -OR 58, -(CH 2) q NR 58 R 59, -C -NR 58 R 59, and -NR 58 -C -C 1-6 alkyl; q is 0 to 4; and r is 1 to 3; wherein the alkyl group, aryl group, hydrocarbon group and/or cycloalkyl group can be optionally substituted with one or more substituents R; wherein a prodrug is a compound in which COOH is replaced by C OR*, wherein R* is selected from H, C 5-10 aryl, C 1-6 alkyl-C 5-10 aryl, C 1-6 alkyl, and C 1-6 alkyl(-O-C 1-6 alkyl) n (with n = 1 to 30); with the proviso that the following compounds are disclaimed: and ethyl 4-oxo-1-{[4-(1H-pyrazolo-1-yl)phenyl]methyl}-1,4-dihydro-1,5-naphthyridine-3-carboxylate. X 51 is CH or N; X 52 -R 54 is N or C-R 57; X 53 is NR 55, N(R 55)C, C NR 55, O, C, C O, OC; N(R 55)SO 2, SO 2 N(R 55), S, SO, or SO 2; R 50 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 51 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; R 52 is -H, a -C 1-6 alkyl group, or a -C 1-6 alkyl group which is substituted by one or more halogen atoms; or wherein R 51 and R 52 can be joined together to form a 3- to 7-membered carbo- or heterocyclic ring; R 53 is -R 56, or -X 53 -R 56; R 55 is -H, -(optionally substituted C 1-6 alkyl), -(optionally substituted C 3-7 cycloalkyl), -(optionally substituted aryl), -C 1-4 alkyl-(optionally substituted C 3-7 cycloalkyl), or -C 1-4 alkyl-(optionally substituted aryl); R 66 is -(optionally substituted hydrocarbon group which contains from 5 to 20 carbon atoms and optionally 1 to 4 heteroatoms selected from O, N and S and which contains at least one ring); R 67 is -H, -Hal or -C 1-6 alkyl; R 58 is -H, -C 1-6 alkyl, or -(CH 2 CH 2 O) r H; R 59 is -H, or -C 1-6 alkyl; R is independently selected from -C 1-6 alkyl, -C -C 1-6 alkyl, -Hal, -CF 3, -CN, -COOR 58, -OR 58, -(CH 2) q NR 58 R 59, -C -NR 58 R 59, and -NR 58 -C -C 1-6 alkyl; q is 0 to 4; and r is 1 to 3;